Last reviewed · How we verify
Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies
This is a single-center, open-label, single-arm study to evaluate the primary safety and efficacy of anti-CD7 chimeric antigen receptor(CAR)-modified T cells(CAR7-Ts) in patients with relapsed or refractory T lymphoid malignancies.
Details
| Lead sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
|---|---|
| Phase | PHASE1 |
| Status | UNKNOWN |
| Enrolment | 24 |
| Start date | Thu Apr 15 2021 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Sun Apr 07 2024 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- T-Cell Lymphocytic Leukemia
- T-Cell Chronic Lymphocytic Leukemia
- T Cell Non-Hodgkin Lymphoma
Interventions
- Fludarabine + Cyclophosphamide + CAR7-T Cells
Countries
China